Use of biologics in SLE:a review of the evidence from a clinical perspective

Aytan, Jayoti and Bukhari, Marwan A. S. (2016) Use of biologics in SLE:a review of the evidence from a clinical perspective. Rheumatology, 55 (5). pp. 775-779. ISSN 1462-0324

Full text not available from this repository.

Abstract

With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in >30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.

Item Type:
Journal Article
Journal or Publication Title:
Rheumatology
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/2700/2736
Subjects:
ID Code:
79732
Deposited By:
Deposited On:
15 Aug 2016 15:30
Refereed?:
Yes
Published?:
Published
Last Modified:
07 Aug 2020 03:48